ARTICLE | Financial News

OptiNose draws down $75M in debt financing

January 5, 2018 9:18 PM UTC

Ear, nose and throat allergy company OptiNose Inc. (NASDAQ:OPTN) said on Jan. 2 it entered a $100 million debt financing agreement with Athyrium Capital Management. At close, $75 million in senior secured notes were issued. OptiNose may draw down the remaining $25 million between April 1, 2019, and Aug. 14, 2019, if the company achieves trailing fourth quarter net revenues of $15 million and a pro forma ratio of total debt to trailing fourth quarter net revenues of 6.5 or less...

BCIQ Company Profiles

OptiNose Inc.

BCIQ Target Profiles

Glucocorticoid receptor (GCCR)